Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Source: Senate LDA
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act ; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act ; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Strengthening Medicare for Patients and Providers Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Strengthening Medicare for Patients and Providers Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Drug Shortage Prevention Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
TREAT Long COVID Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
TREAT Long COVID Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
TREAT Long COVID Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
TREAT Long COVID Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
PATIENT Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
PATIENT Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Providing Relief and Stability for Medicare Patients Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Ensuring Access to Lifesaving Drugs Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Ensuring Access to Lifesaving Drugs Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
TACT Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
TACT Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
TACT Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act ; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
TACT Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Preparedness and Response Reauthorization Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Preparedness and Response Reauthorization Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Medicare Patient Access to Cancer Treatment Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Medicare Patient Access to Cancer Treatment Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Block, Report, and Suspend Suspicious Shipments Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Block, Report, and Suspend Suspicious Shipments Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Lower Costs, More Transparency Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act ; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Pharmacy Benefit Manager Transparency Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Pharmacy Benefit Manager Reform Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Pharmacy Benefit Manager Reform Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Pandemic and All-Hazards Preparedness and Response Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Pandemic and All-Hazards Preparedness and Response Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
MAPS Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
RAPID Reserve Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Supporting Medicare Providers Act of 2022
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Supporting Medicare Providers Act of 2022
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
Lower Costs, More Cures Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Lower Costs, More Cures Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Lower Costs, More Cures Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R.7213 Clinical trial diversity, health equity. S.3799 Emergency preparedness and response. H.R.6000 Healthcare innovation, ARPA-H, oncology research. H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacist equitable access, health equity. H.R. 7213 Clinical trial diversity, health equity. H.R. 5030/S. 2706 Emergency preparedness and response. S. 3799 Healthcare innovation, ARPA-H, oncology research. H.R. 6000 Laboratory diagnostic services, schedule reimbursement S. 4449 Omnibus federal appropriations Pandemic Response Biden Cancer Moonshot Initiative H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act. H.R. 8800 Supporting Medicare Providers Act of 2022
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacist equitable access, health equity. H.R. 7213 Clinical trial diversity, health equity. H.R. 5030/S. 2706 Emergency preparedness and response. S. 3799 Healthcare innovation, ARPA-H, oncology research. H.R. 6000 Laboratory diagnostic services, schedule reimbursement S. 4449 Omnibus federal appropriations Pandemic Response Biden Cancer Moonshot Initiative H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act. H.R. 8800 Supporting Medicare Providers Act of 2022
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Social Determinants Accelerator Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Social Determinants Accelerator Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Social Determinants Accelerator Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Social determinants of health; health disparities in underserved communities; chronic health conditions H.R.2503,; Drug pricing and transparency, access and adherence,; Domestic sourcing and production,; COVID relief and pandemic response, pandemic preparedness; Supply chain, global operations, trade.
Social Determinants Accelerator Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Social determinants of health; health disparities in underserved communities; chronic health conditions H.R.2503,; Drug pricing and transparency, access and adherence,; Domestic sourcing and production,; COVID relief and pandemic response, pandemic preparedness; Supply chain, global operations, trade.
Social Determinants Accelerator Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Social determinants of health; health disparities in underserved communities; chronic health conditions H.R.2503,; Drug pricing and transparency, access and adherence,; Domestic sourcing and production,; COVID relief and pandemic response, pandemic preparedness; Supply chain, global operations, trade.
Social Determinants Accelerator Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Elijah E. Cummings Lower Drug Costs Now Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Elijah E. Cummings Lower Drug Costs Now Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Elijah E. Cummings Lower Drug Costs Now Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act. H.R.7213 Pharmacist equitable access, health equity. H.R.6000 Healthcare innovation, ARPA-H, oncology research.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act ; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
S.4449 Laboratory diagnostic services, schedule reimbursement. H.R.7213 Pharmacist equitable access, health equity. S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act. H.R. 3258 Timely Access to Cancer Treatment.
H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act. H.R.7213 Pharmacist equitable access, health equity. H.R.6000 Healthcare innovation, ARPA-H, oncology research.
Pharmacist equitable access, health equity. H.R. 7213 Clinical trial diversity, health equity. H.R. 5030/S. 2706 Emergency preparedness and response. S. 3799 Healthcare innovation, ARPA-H, oncology research. H.R. 6000 Laboratory diagnostic services, schedule reimbursement S. 4449 Omnibus federal appropriations Pandemic Response Biden Cancer Moonshot Initiative H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act. H.R. 8800 Supporting Medicare Providers Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Pharmacist equitable access, health equity. H.R. 7213 Clinical trial diversity, health equity. H.R. 5030/S. 2706 Emergency preparedness and response. S. 3799 Healthcare innovation, ARPA-H, oncology research. H.R. 6000 Laboratory diagnostic services, schedule reimbursement S. 4449 Omnibus federal appropriations Pandemic Response Biden Cancer Moonshot Initiative H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act. H.R. 8800 Supporting Medicare Providers Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
H.R.7213 Clinical trial diversity, health equity. S.3799 Emergency preparedness and response. H.R.6000 Healthcare innovation, ARPA-H, oncology research. H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Social determinants of health; health disparities in underserved communities; chronic health conditions H.R.2503,; Drug pricing and transparency, access and adherence,; Domestic sourcing and production,; COVID relief and pandemic response, pandemic preparedness; Supply chain, global operations, trade.
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Social determinants of health; health disparities in underserved communities; chronic health conditions H.R.2503,; Drug pricing and transparency, access and adherence,; Domestic sourcing and production,; COVID relief and pandemic response, pandemic preparedness; Supply chain, global operations, trade.
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Social determinants of health; health disparities in underserved communities; chronic health conditions H.R.2503,; Drug pricing and transparency, access and adherence,; Domestic sourcing and production,; COVID relief and pandemic response, pandemic preparedness; Supply chain, global operations, trade.
Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration; H.R.2503; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
The Social Determinants Accelerator Act, S.4264; U.S. MADE Act of 2020, H.R. 6880; MADE in America Act, H.R.3; Oncology Care Model; Radiation Oncology APM; Lower Drug Costs Now Act of 2019, H.R.1845; ALERT Act of 2019; Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748; CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution. H.R.2503 - The Social Determinants Accelerator Act of 2021, H.R.3 - Drug pricing and transparency, H.R.3, H.R.19; Budget Reconciliation; International price referencing, H.R.19; Medical Supplies for Pandemics Act of 2021, S.65; Improving Seniors Timely Access to Care Act, H.R. 3173; Safe Step Act, 2163; Buy America and domestic sourcing, strategic national stockpile H.R.3635; S.308; H.R.2780; Supply chain, global operations, trade; Opioids, substance abuse and prescription safety alert systems; Issues remain the same with addition of Build Back Better Act, H.R.5376.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. H.R. 6637, the Health Equity and Accountability Act (HEAA), H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act, S.4264 - U.S. MADE Act of 2020, H.R. 6880 - The Buy American Medical Supplies Act, H.R. 6930 - MADE in America Act, H.R. 3 Lower Drug Costs Now Act of 2019, H.R.1845 - ALERT Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748 - CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution. H.R.2503 - The Social Determinants Accelerator Act of 2021, H.R. 3, Drug pricing and transparency, H.R. 16 International price referencing, S.1693 - Medical Supplies for Pandemics Act of 2021, S.65 - Uyghur Forced Labor Prevention Act, H.R. 3173, Improving Seniors Timely Access to Care Act, H.R. 2163 - Safe Step Act
H.R./S.1: Tax Cuts and Jobs Act.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration
USTR Section 301 proposed tariffs.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution
USTR Section 301 proposed tariffs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. H.R. 6637, the Health Equity and Accountability Act (HEAA), H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act, S.4264 - U.S. MADE Act of 2020, H.R. 6880 - The Buy American Medical Supplies Act, H.R. 6930 - MADE in America Act, H.R. 3 Lower Drug Costs Now Act of 2019, H.R.1845 - ALERT Act of 2019
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
H.R./S.1: Tax Cuts and Jobs Act.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
H.R./S.1: Tax Cuts and Jobs Act.
USTR Section 301 proposed tariffs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
USTR Section 301 proposed tariffs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
USTR Section 301 proposed tariffs.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
H.R./S.1: Tax Cuts and Jobs Act.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment.
H.R./S.1: Tax Cuts and Jobs Act.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
USTR Section 301 proposed tariffs.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; Issues related to reimbursement from the Department of Veterans Affairs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316)
Proposal to repeal LIFO; Corporate Tax Reform
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues.
Incentives for health information technology, proposed legislation regarding standards for licensure of medical supply distributors; education regarding Appropriate Use Criteria Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local coverage determination process (S.794); Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014; General Medicare/Medicaid Issues.
Proposal to repeal LIFO
Incentives for health information technology, proposed legislation regarding standards for licensure of medical supply distributors; education regarding Appropriate Use Criteria Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local coverage determination process (S.794)
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Proposals to repeal LIFO
Education regarding existing Department of Veterans' Affairs Pharmaceutical Prime Vendor Contract
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Incentives for health information technology, proposed regulation of medical software, proposals to promote healthcare interoperability, and other healthcare policy issues. S. 1101, MEDTECH Act; S. 2141, Trust IT Act; proposed legislation regarding licensure of medical supply distributors
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Incentives for health information technology, proposed regulation of medical software, proposals to promote healthcare interoperability, and other healthcare policy issues. S. 1101, MEDTECH Act; S. 2141, Trust IT Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion, H.R. 471 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S. 483 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S.524 "Comprehensive Addiction and Recovery Act of 2016".
Incentive for health information technology, Affordable Care Act, proposed regulation of medical software, proposals to promote healthcare interoperability, and other healthcare policy issues. H.R. 6, 21st Century Cures Act; H.R. 2396, SOFTWARE Act, S. 1101, MEDTECH Act; S. 2141, Trust IT Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion, H.R. 471 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S. 483 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015"
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Tax policy; LIFO-last-in, first-out; foreign earnings, corporate tax rate; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
The Social Determinants Accelerator Act, S.4264; U.S. MADE Act of 2020, H.R. 6880; MADE in America Act, H.R.3; Oncology Care Model; Radiation Oncology APM; Lower Drug Costs Now Act of 2019, H.R.1845; Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748; CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution. H.R.2503 - The Social Determinants Accelerator Act of 2021, H.R.3 - Drug pricing and transparency, H.R.3, H.R.19; Budget Reconciliation; International price referencing, H.R.19; Medical Supplies for Pandemics Act of 2021, S.65; Improving Seniors Timely Access to Care Act, H.R. 3173; Safe Step Act, 2163; Buy America and domestic sourcing, strategic national stockpile H.R.3635; S.308; H.R.2780; global operations, trade; Opioids, substance abuse and prescription safety alert systems; Issues remain the same with addition of Build Back Better Act, H.R.5376; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution; S.1362; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution
USTR Section 301 proposed tariffs.
H.R./S.1: Tax Cuts and Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. H.R. 6637, the Health Equity and Accountability Act (HEAA), H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act, S.4264 - U.S. MADE Act of 2020, H.R. 6880 - The Buy American Medical Supplies Act, H.R. 6930 - MADE in America Act, H.R. 3 Lower Drug Costs Now Act of 2019, H.R.1845 - ALERT Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748 - CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution
USTR Section 301 proposed tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. H.R. 6637, the Health Equity and Accountability Act (HEAA), H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act, S.4264 - U.S. MADE Act of 2020, H.R. 6880 - The Buy American Medical Supplies Act, H.R. 6930 - MADE in America Act, H.R. 3 Lower Drug Costs Now Act of 2019, H.R.1845 - ALERT Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748 - CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution
H.R./S.1: Tax Cuts and Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019
H.R./S.1: Tax Cuts and Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
USTR Section 301 proposed tariffs.
H.R./S.1: Tax Cuts and Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R./S.1: Tax Cuts and Jobs Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
USTR Section 301 proposed tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USTR Section 301 proposed tariffs.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
USTR Section 301 proposed tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
H.R./S.1: Tax Cuts and Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
H.R./S.1: Tax Cuts and Jobs Act.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R./S.1: Tax Cuts and Jobs Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
USTR Section 301 proposed tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
USTR Section 301 proposed tariffs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R./S.1: Tax Cuts and Jobs Act.
USTR Section 301 proposed tariffs.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals;education about potential improvements to Prescription Drug Monitoring Programs.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
H.R./S.1: Tax Cuts and Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R./S.1: Tax Cuts and Jobs Act.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R./S.1: Tax Cuts and Jobs Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Incentives for health information technology including the adoption of electronic health records; Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Education around Electronic Health Records and Rx distribution at the VA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Incentives for health information technology, proposed regulation of medical software, proposals to promote healthcare interoperability, and other healthcare policy issues. S. 1101, MEDTECH Act; S. 2141, Trust IT Act; proposed legislation regarding licensure of medical supply distributors; H.R.34, 21st Century Cures Act
Education regarding existing Department of Veterans' Affairs Pharmaceutical Prime Vendor Contract
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion, S.524 "Comprehensive Addiction and Recovery Act of 2016".
Incentives for health information technology, proposed regulation of medical software, proposals to promote healthcare interoperability, and other healthcare policy issues. S. 1101, MEDTECH Act; S. 2141, Trust IT Act; proposed legislation regarding licensure of medical supply distributors
Proposals to repeal LIFO
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion, H.R. 471 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S. 483 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S.524 "Comprehensive Addiction and Recovery Act of 2016".
Education regarding existing Department of Veterans' Affairs Pharmaceutical Prime Vendor Contract
Proposals to repeal LIFO
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposals to repeal LIFO
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Education regarding existing Department of Veterans' Affairs Pharmaceutical Prime Vendor Contract
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015
Proposals to repeal LIFO
Education regarding existing Department of Veterans' Affairs Pharmaceutical Prime Vendor Contract
Filing targets: HOUSE OF REPRESENTATIVES, SENATE